Vigil Neuroscience, Inc. (NASDAQ:VIGL) Director Haeberlein Samantha L. Budd Buys 12,000 Shares

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Director Haeberlein Samantha L. Budd bought 12,000 shares of the company’s stock in a transaction dated Thursday, December 19th. The stock was acquired at an average price of $1.71 per share, for a total transaction of $20,520.00. Following the acquisition, the director now directly owns 12,000 shares in the company, valued at $20,520. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Vigil Neuroscience Stock Performance

Shares of VIGL opened at $1.70 on Friday. The firm has a market cap of $69.49 million, a PE ratio of -0.83 and a beta of 1.65. The firm’s 50 day moving average price is $3.02 and its 200 day moving average price is $3.49. Vigil Neuroscience, Inc. has a twelve month low of $1.60 and a twelve month high of $6.06.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of VIGL. Ensign Peak Advisors Inc boosted its holdings in Vigil Neuroscience by 72.8% in the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after purchasing an additional 166,442 shares in the last quarter. abrdn plc acquired a new stake in shares of Vigil Neuroscience in the third quarter worth about $799,000. Point72 Asset Management L.P. bought a new stake in shares of Vigil Neuroscience during the 2nd quarter worth about $5,940,000. Verition Fund Management LLC acquired a new position in shares of Vigil Neuroscience during the 3rd quarter valued at about $442,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Vigil Neuroscience in the 2nd quarter valued at approximately $87,000. Institutional investors own 83.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on VIGL shares. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Vigil Neuroscience in a research report on Friday, November 8th. JMP Securities reissued a “market outperform” rating and set a $22.00 target price on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Wedbush upped their price target on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Finally, William Blair began coverage on Vigil Neuroscience in a research report on Wednesday, December 4th. They set an “outperform” rating for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $19.75.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.